Appian To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Tuesday
Portfolio Pulse from Lisa Levin
Top Wall Street analysts have updated their outlooks on several stocks. Alteryx's price target was increased by Piper Sandler from $30 to $32, while IAC's price target was cut by Keybanc from $81 to $72. DA Davidson raised Appian's price target from $50 to $55, and Morgan Stanley cut RE/MAX's price target from $19.5 to $9. Other companies mentioned include Mirati Therapeutics, Alphatec Holdings, Alto Ingredients, EverQuote, Ventas, and Compass.
November 07, 2023 | 12:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
DA Davidson raised Appian's price target from $50 to $55, upgrading the stock from Neutral to Buy.
The increase in price target and upgrade to Buy by DA Davidson indicates a positive outlook for Appian, which could lead to a short-term increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Piper Sandler increased Alteryx's price target from $30 to $32, maintaining an Underweight rating.
The increase in price target by Piper Sandler indicates a positive outlook for Alteryx, which could lead to a short-term increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Keybanc cut IAC's price target from $81 to $72, maintaining an Overweight rating.
The decrease in price target by Keybanc indicates a negative outlook for IAC, which could lead to a short-term decrease in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Morgan Stanley cut RE/MAX's price target from $19.5 to $9, downgrading the stock from Equal-Weight to Underweight.
The decrease in price target and downgrade to Underweight by Morgan Stanley indicates a negative outlook for RE/MAX, which could lead to a short-term decrease in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100